|
12/05/24
|
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
|
|
|
11/06/24
|
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
|
|
|
09/03/24
|
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
|
|
|
08/14/24
|
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
|
|
|
08/01/24
|
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
|
|
|
06/03/24
|
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
|
|
|
05/07/24
|
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
|
|
|
05/01/24
|
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
|
|
|
02/27/24
|
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
|
|
02/27/24
|
Denali Therapeutics Announces $500 million Private Placement Equity Financing
|
|